ScoreWhy is Astrazeneca Pharma India Ltd ?
1
High Management Efficiency with a high ROE of 21.62%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
The company has declared Positive results for the last 4 consecutive quarters
- OPERATING CF(Y) Highest at Rs 65.36 Cr
- DPS(Y) Highest at Rs 32.00
- PAT(Latest six months) At Rs 114.26 cr has Grown at 35.70%
4
With ROE of 29.1, it has a Very Expensive valuation with a 28.4 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 36.58%, its profits have risen by 66.5% ; the PEG ratio of the company is 1.5
5
Majority shareholders : Promoters
6
Consistent Returns over the last 3 years
- Along with generating 36.58% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Astrazeneca Phar for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
17.82%
1.03
35.48%
Sensex
8.49%
0.43
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.54%
EBIT Growth (5y)
22.96%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.88
Tax Ratio
25.69%
Dividend Payout Ratio
69.12%
Pledged Shares
0
Institutional Holding
8.27%
ROCE (avg)
97.56%
ROE (avg)
21.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
92
Industry P/E
32
Price to Book Value
26.86
EV to EBIT
77.05
EV to EBITDA
65.98
EV to Capital Employed
48.62
EV to Sales
10.51
PEG Ratio
1.39
Dividend Yield
0.37%
ROCE (Latest)
63.10%
ROE (Latest)
29.06%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend20What is working for the Company
OPERATING CF(Y)
Highest at Rs 65.36 Cr
DPS(Y)
Highest at Rs 32.00
PAT(Latest six months)
At Rs 114.26 cr has Grown at 35.70%
ROCE(HY)
Highest at 37.81%
NET SALES(Q)
Highest at Rs 559.09 cr
DPR(Y)
Highest at 69.12%
PBT LESS OI(Q)
Highest at Rs 71.94 cr.
-2What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 399.94 cr
Loading Valuation Snapshot...
Here's what is working for Astrazeneca Phar
Net Sales - Quarterly
Highest at Rs 559.09 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
At Rs 114.26 cr has Grown at 35.70%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Operating Cash Flow - Annually
Highest at Rs 65.36 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Dividend per Share (DPS) - Annually
Highest at Rs 32.00 and Grown
each year in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (Rs)
Net Sales - Quarterly
At Rs 559.09 cr has Grown at 20.6% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 463.77 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 71.94 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Dividend Payout Ratio (DPR) - Annually
Highest at 69.12%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Here's what is not working for Astrazeneca Phar
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 399.94 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
